High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (Oligo)

  • End date
    Oct 8, 2026
  • participants needed
  • sponsor
    The Netherlands Cancer Institute
Updated on 8 April 2022
endocrine therapy
hormone therapy
primary tumor
stage iv breast cancer
invasive breast cancer


This study investigates the effect of high-dose alkylating chemotherapy compared with standard chemotherapy as part of a multimodality treatment approach in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency.

Condition Breast Cancer
Treatment carboplatin, thiotepa, and cyclophosphamide, chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
Clinical Study IdentifierNCT01646034
SponsorThe Netherlands Cancer Institute
Last Modified on8 April 2022


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed infiltrating breast cancer
Oligometastatic disease defined as one to three distant metastatic lesions, with or without primary tumor, local recurrence, or locoregional lymph node metastases, including the ipsilateral axillary, parasternal, and periclavicular regions. All lesions must be amenable to resection or radiotherapy with curative intent. Staging examinations must have included a PET-CT-scan and a MRI of the liver in case of liver metastases. Clustered lymph nodes that can be irradiated with curative intent in a single field are defined as a single lesion. Histologic or cytologic confirmation of at least one distant metastatic lesion is required
No prior line of chemotherapy for metastatic disease (a maximum of 3 months of palliative endocrine therapy is allowed)
The tumor must be HER2-negative (either score 0 or 1 at immunohistochemistry or negative at in situ hybridization in case of score 2 or 3 at immunohistochemistry)
The tumor is deficient in homologous recombination and/or the patient has a deleterious germline BRCA1 or BRCA2 mutation
At least stable disease of all tumor lesions after three courses of induction chemotherapy
Age ≥18 years
World Health Organisation (WHO) performance status 0 or 1
Adequate bone marrow function (ANC ≥1.0 x 109/l, platelets ≥100 x 109/l)
Adequate hepatic function (ALAT, ASAT and bilirubin ≤2.5 times upper limit of normal)
Adequate renal function (creatinine clearance ≥60 ml/min)
If clinically recommended echocardiography, MUGA, or MRI to evaluate if LVEF ≥50%
Signed written informed consent
Able to comply with the protocol

Exclusion Criteria

No malignancy other than breast cancer, unless treated with curative intent without the use of chemotherapy or radiation therapy
No current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection
No concurrent anti-cancer treatment or investigational drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note